Stock News & Analysis

Defense spending is on the rise around the world, and these two companies are set for some serious growth because of it.

Tesla sells cars -- and the auto industry is notoriously cyclical. But Tesla's structure and long-term strategy may give it more resilience than its peers.

Oil pushing toward $100 can make energy dividends look irresistible, but the best picks are the ones that don't need $100 oil to keep paying you. Here are two dividend giants that have already proven their payouts can hold up when the cycle turns.

These companies boast strong sales and compelling share price valuations.

Oil prices go up, and they go down; these high-yield energy businesses don't really care.

Nvidia is riding a multiyear demand wave.

Amazon's stock behavior differed greatly from CrowdStrike's reaction to its 2024 outage.

A blockbuster deal with an artificial intelligence (AI) giant has investors excited.

While both of these iconic consumer brands offer dividends, one stands out as the better buy today.

Invesco DWA Momentum ETF tracks a diversified portfolio of U.S. equities selected for strong relative strength characteristics.

This technology ETF tracks the NASDAQ-100 sector with an equal-weighted strategy, offering diversified exposure to large-cap tech equities.

Oracle has guided for tremendous revenue growth in its cloud infrastructure business over its next four fiscal years.

Some stocks can perform well even during a recession.

Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology.

The company recently unveiled its R2 lineup.

nLIGHT, a leader in advanced laser solutions for industry and defense, just reported a notable insider sale amid standout 1-year returns.

This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases.

Seniors get a generous new tax deduction, but there's only a limited time to claim it.

CoreWeave is posting incredible top-line growth, but its staggering costs and capital requirements make the stock too speculative for my portfolio.

This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.